Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 1—January 2016

Research

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

Ross L. CameronComments to Author , Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, and Kevin G.J. Pollock
Author affiliations: Health Protection Scotland, Glasgow, Scotland, UK (R.L. Cameron, J. Love, S. Ahmed, K.G.J. Pollock); University of Strathclyde, Glasgow (K. Kavanagh, J. Pan, C. Robertson); Scottish Human Papillomavirus Reference Laboratory, Edinburgh, Scotland, UK (K. Cuschieri); University of Edinburgh, Edinburgh (T. Palmer)

Main Article

Figure

Analyses for 5,715 liquid-based cytology cervical samples from vaccinated and nonvaccinated women, for which valid human papillomavirus (HPV) testing results were available, Scotland, 2009–2013. A) Proportion and 95% CIs for samples with positive results for each HPV type. B) Difference in the proportion positive and associated 95% CIs for the difference by HPV type. Other than HPV types 16 and 18, the 95% CIs of the difference were corrected for multiple testing using by using the Bonferroni co

Figure. Analyses for 5,715 liquid-based cytology cervical samples from vaccinated and nonvaccinated women, for which valid human papillomavirus (HPV) testing results were available, Scotland, 2009–2013. A) Proportion and 95% CIs for samples with positive results for each HPV type. B) Difference in the proportion positive and associated 95% CIs for the difference between vaccinated and nonvaccinated women, by HPV type. Other than HPV types 16 and 18, the 95% CIs of the difference were corrected for multiple testing using by using the Bonferroni correction. *Significant change.

Main Article

TOP